La bronchopneumopathie chronique obstructive. Une maladie inflammatoire  chronique.

Bronchi; Comorbidity; Humans; Inflammation/complications; Lung; Pulmonary Disease, Chronic Obstructive/complications/therapy; Inflammation; Treatment; COPD

Abstract :

[en] Chronic Obstructive Pulmonary Disease (COPD) is a disease caused by a chronic inflammatory response induced by the inhalation of cigarette smoke or toxic particles/gases in the airways. However, we actually know that COPD is a disease that does not only induce inflammation in lung parenchyma and bronchi, but also provokes systemic inflammation which plays a role in multiple comorbidities. Thereby, treatment of COPD should not only focus on the bronchi to relieve symptoms, improve respiratory function and reduce the rate of exacerbations, but must also be extended to the systemic effects of the disease.

Disciplines :

Cardiovascular & respiratory systems

Author, co-author :

Corhay, Jean-Louis ; Centre Hospitalier Universitaire de Liège - CHU > > Service de pneumologie - allergologie

Bonhomme, Olivier ; Centre Hospitalier Universitaire de Liège - CHU > > Service de pneumologie - allergologie

HEINEN, Vincent ; Centre Hospitalier Universitaire de Liège - CHU > > Service de pneumologie - allergologie

Moermans, Catherine ; Centre Hospitalier Universitaire de Liège - CHU > > Service de pneumologie - allergologie

Louis, Renaud ; Centre Hospitalier Universitaire de Liège - CHU > > Service de pneumologie - allergologie

Language :

French

Title :

La bronchopneumopathie chronique obstructive. Une maladie inflammatoire chronique.

Alternative titles :

[en] Chronic obstructive pulmonary disease. A chronic inflammatory disease.

Publication date :

May 2022

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Université de Liège. Revue Médicale de Liège, Liège, Be

Volume :

Issue :

5-6

Pages :

295-301

Peer reviewed :

Editorial Reviewed verified by ORBi

Available on ORBi :

since 05 January 2023

Statistics

Number of views

126 (3 by ULiège)

Number of downloads

533 (6 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenAlex citations

Bibliography

Global initiative for Obstructive Lung Disease: mise à jour en 2021;disponible sur www.goldcopd.org.
Wouters EF. Local and systemic inflammation in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005;2:26-33.
Barnes PJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol 2016;138:16-27.
Hogg J.C, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004;350:2645-53.
Corhay JL, Frusch N, Louis R. Interrelations génétique-environnement: «La broncho-pneumopathie chronique obstructive». Rev Med Liege 2012;67:292-7.
Moermans C, Heinen V, Nguyen M, et al. Local and systemic cellular inflammation and cytokine release in chronic obstructive pulmonary disease. Cytokine 2011;56:298-304.
Corhay J-L, Hemmelaers L, Henket M, et al. Granulocyte chemotactic activity in exhaled breath condensate of healthy subjects and COPD. Chest 2007;131:1672 -77.
Debrus C, Bonhomme O, Corhay JL. Réduction des exacerbations dans la BPCO: défi en 2017. Rev Med Liege 2017;72:74-80.
Schleich F, Corhay J-L J-L, Louis R. Blood eosinophil count to predict bronchial eosinophilic inflammation in COPD. Eur Respir J 2016;47:1562-4.
Cardoso J, Ferreira AJ, Guimarães M, et al. Treatable traits in COPD-A proposed approach. Int J Chron Obstruct Pulmon Dis 2021;16:3167-82.
Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med 2018;378:1671-80.
Rabe KF, Martinez FJ, Ferguson GT, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med 2020;383:35-48.
Papi A, Vestbo J, Fabbri L, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet 2018;391:1076-84.
Zarogoulidis P, Papanas N, Kioumis I, et al. Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases. Eur J Clin Pharmacol 2012;68:479-503.
Pavord ID, Chapman KR, Bafadhel M, et al. Mepolizumab for eosinophil-associated COPD: analysis of METREX and METREO. Int J Chron Obstruct Pulmon Dis 2021;16:1755-70.
Criner GJ, Celli BR, Singh D, et al. Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies. Lancet Respir Med 2020;8:158-70.
Wedzicha JA, Calverley PMA, Rabe KF. Roflumilast: a review of its use in the treatment of COPD. Int J Chron Obstruct Pulmon Dis 2016;11:81-90.
Barnes, PJ. New anti-inflammatory targets for chronic obstructive pulmonary disease. Nat Rev Drug Discov 2013;12:543-59.
van Haarst A, McGarvey L, Paglialunga S. Review of drug development guidance to treat chronic obstructive pulmonary disease: US and EU perspectives. Clin Pharmacol Ther 2019;106:1222-35.
Negewo NA, McDonald VM, Gibson PG. Comorbidity in chronic obstructive pulmonary disease. Respir Investig 2015;53:249-58.
Finkelstein J, Cha E, Scharf SM. Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity. Int J Chron Obstruct Pulmon Dis 2009;4:337-49.
Wouters EFM, Creutzberg EC, Schols AM. Systemic effects in COPD. Chest 2002;121:127S-30S.
Aisanov Z, Khaltaev N. Management of cardiovascular comorbidities in chronic obstructive pulmonary disease patients. J Thorac Dis 2020;12:2791-802.
Gläser S, Krüger S, Merkel M, et al. Chronic obstructive pulmonary disease and diabetes mellitus: a systematic review of the literature. Respiration 2015;89:253-64.
Pirotte M, Guiot J, Beguin Y, Louis R. L’anémie dans la bronchopneumopathie chronique sévère: une comorbidité plus fréquente qu’on ne le croit. Rev Med Liege 2016;71:488-94.
Biskobing DM. COPD and osteoporosis. Chest 2002;121:609-20.
Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: role of comorbidities. Eur Respir J 2006;28:1245-57.
Cavaillès A, Brinchault-Rabin G, Dixmier A, et al. Comorbidities of COPD. Eur Respir Rev 2013;22:454-75.
King PT. Inflammation in chronic obstructive pulmonary disease and its role in cardiovascular disease and lung cancer. Clin Transl Med 2015;4:68.
Strollo H. C. Nouraie SM, Hoth KF, et al. Association of systemic inflammation with depressive symptoms in individuals with COPD. Int J of Chron Obstruct Pulmon Dis 2021;16:2515-22.
McGarvey LP, John M, Anderson JA, et al. Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax 2007;62:411-5.
Corhay JL, Nguyen Dang D, Van Cauwenberge H, Louis R. Pulmonary rehabilitation and COPD: providing patients a good environment for optimizing therapy. Int J Chron Obstruct Pulmon Dis 2014;9:27-39.
Short P.M, Lipworth S.I,Elder D.H, et al. Effect of β blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. BMJ 2011;342:d2549.
Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnoea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004;350:1005-12.
Kahnert K, Jörres RA, Lucke T, et al. Lower prevalence of osteoporosis in patients with COPD taking anti-inflammatory compounds for the treatment of diabetes: results from COSYCONET. Int J Chron Obstruct Pulmon Dis 2021;16:3189-99.